DrugPatentWatch Database Preview
Intersect Ent Inc Company Profile
What is the competitive landscape for INTERSECT ENT INC, and when can generic versions of INTERSECT ENT INC drugs launch?
There are ten US patents protecting INTERSECT ENT INC drugs.
There are twenty-four patent family members on INTERSECT ENT INC drugs in ten countries and two supplementary protection certificates in two countries.
Summary for Intersect Ent Inc
| International Patents: | 24 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Intersect Ent Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intersect Ent Inc | SINUVA | mometasone furoate | IMPLANT;IMPLANTATION | 209310-001 | Dec 8, 2017 | RX | Yes | No | 7,662,141 | ➤ Sign Up | ➤ Sign Up | ||||
| Intersect Ent Inc | SINUVA | mometasone furoate | IMPLANT;IMPLANTATION | 209310-001 | Dec 8, 2017 | RX | Yes | No | 7,951,130 | ➤ Sign Up | ➤ Sign Up | ||||
| Intersect Ent Inc | SINUVA | mometasone furoate | IMPLANT;IMPLANTATION | 209310-001 | Dec 8, 2017 | RX | Yes | No | 8,763,222 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Intersect Ent Inc | SINUVA | mometasone furoate | IMPLANT;IMPLANTATION | 209310-001 | Dec 8, 2017 | RX | Yes | No | 7,713,255 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Intersect Ent Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,782,283 | Methods and devices for crimping self-expanding devices | ➤ Sign Up |
| 7,691,094 | Sinus delivery of sustained release therapeutics | ➤ Sign Up |
| 8,858,974 | Device and methods for treating paranasal sinus conditions | ➤ Sign Up |
| 7,662,142 | Sinus delivery of sustained release therapeutics | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Intersect Ent Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2320832 | ➤ Sign Up |
| Japan | 2006520786 | ➤ Sign Up |
| European Patent Office | 1605863 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2006107957 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Intersect Ent Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0002 | Belgium | ➤ Sign Up | PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622 |
| C/GB97/064 | United Kingdom | ➤ Sign Up | PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
